Clinical trial
Study Evaluating Mitoxantrone in Multiple Sclerosis
NCT00146159 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00146159 |
|---|---|
| Title | Study Evaluating Mitoxantrone in Multiple Sclerosis |
| Official title | A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Secondary Progressive Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Mitoxantrone |
| Enrollment | 336 |
| Start date | Mar 1, 2005 |
| Primary completion | Sep 1, 2007 |
| First posted | Sep 5, 2005 |
| Last update posted | Dec 28, 2007 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: